Table 2. Clinicopathological features, tumor markers, EZH2, and uveal melanoma patients’ survival.
| Total N (%) | No.of events | Univariate HR(95% CI) | P | Multivariate HR1 (95% CI) | P | ||
|---|---|---|---|---|---|---|---|
| Disease-free survival | |||||||
| Epithelioid cells | No | 76(85%) | 25 | 1(reference) | 1(reference) | ||
| Yes | 13(15%) | 6 | 3.90(1.23 to 12.33) | 0.021 | 2.22(0.64 to 7.70) | 0.208 | |
| Mitoses count | ≤4 | 69(76%) | 14 | 1(reference) | 1(reference) | ||
| >4 | 20(24%) | 17 | 1.40(1.23 to 1.59) | 0.0001 | 1.39(1.19 to 1.62) | 0.0001 | |
| Ki67 LI | ≤2 | 70(79%) | 18 | 1(reference) | 1(reference) | ||
| >2 | 19(21%) | 13 | 1.23(1.05 to 1.45) | 0.012 | 1.64(1.09 to 2.46) | 0.019 | |
| EZH2 | Low | 58(65%) | 20 | 1(reference) | 1(reference) | ||
| High | 31(35%) | 11 | 3.64(1.09 to 8.11) | 0.035 | 2.12(0.51 to 8.85) | 0.037 | |
| Disease-specific survival | |||||||
| Epithelioid cells | No | 76(85%) | 25 | 1(reference) | 1(reference) | ||
| Yes | 13(15%) | 6 | 3.62(1.24 to 11.46) | 0.029 | 2.00(0.59 to 6.78) | 0.267 | |
| Mitoses count | ≤4 | 69(76%) | 14 | 1(reference) | 1(reference) | ||
| >4 | 20(24%) | 17 | 1.43(1.25 to 1.64) | 0.0001 | 1.39(1.20 to 1.62) | 0.0001 | |
| Ki67 LI | ≤2 | 70(79%) | 18 | 1(reference) | 1(reference) | ||
| >2 | 19(21%) | 13 | 1.22(1.04 to 1.44) | 0.017 | 1.45(1.02 to 2.08) | 0.041 | |
| EZH2 | Low | 58(65%) | 20 | 1(reference) | 1(reference) | ||
| High | 31(35%) | 11 | 5.17(1.42 to 8.80) | 0.013 | 3.92(1.44 to 7.85) | 0.036 | |
HR, hazard ratio; CI, confidence interval.
1The multivariate Cox regression model initially included the EZH2 expression variable (high or low), age of diagnosis, sex, largest basal tumor diameter, tumor thickness and epithelioid cell pattern.